Amesite Operating Co is projected to report Q2 2026 revenue of $0.95 million and an EPS loss of $0.10, with the current stock price of $2.85 trading well below the $6.00 average analyst price target. Investors are primarily focused on the revenue growth contribution from the NurseHub platform and its impact on the company's path to profitability. This report follows a period of strategic focus on AI-integrated healthcare education and the expansion of high-margin B2B SaaS partnerships. Management's ability to demonstrate improved scalability in its AI-driven training modules will be critical for sustaining the stock's recent recovery momentum.